| abstract |
The invention relates to the use of quinazolines of general formula (1) wherein A, B, C, D, X, Ra, Rb, Rc and n have the designations defined in cla im 1, or the compounds (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-dimethylami no- cyclohexyl)amino]-pyrimido[5,4-d]pyrimidine, (2) 4-[(R)-(1-phenylethyl)amino ]- 6-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine, (3) 4-{[3-chloro-4-(3-fluor o- 4-benzyloxy)-phenyl]amino}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}-fura n- 2-yl)quinazoline, or the antibodies Cetuximab C225, Trastuzumab, ABX-EGF, Ma b ICR-62 and EGFR-antisense, and the tautomers, stereoisomers and salts thereo f, especially the physiologically compatible salts thereof comprising inorganic or organic acids or bases, for producing a medicament for the prevention or treatment of respiratory tract diseases or pulmonary diseases. |